Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy
- Written by PR Newswire
- Grant funding will support Save our Sons Duchenne Foundation in developing a digital health app -
SYDNEY, Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that an Australian patient advocacy organization is one of the two recipients of the company's 2023 STRIVE Awards. The program provides grants to...